MetaCap

Tarsus Pharmaceuticals Inc. (TARS)

NASDAQ: TARSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

73.01-4.66 (-6.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TARS stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$15.86
52-week range
53.89 – 91.53
Day range
72.74 – 78.11
Volume / Avg
706.77K / 871.07K
Beta
—

52-week range

$53.89$91.53

TARS stock today

Tarsus Pharmaceuticals (TARS) closed at $73.01 on Nov 20, down 6.00% (-$4.66), versus the S&P 500's 3.70% decline. At this level, TARS sits in the middle of its 52-week range of $53.89 to $91.53: 20.2% below the high, set on Sep 4, 2026 and 35.5% above the low. TARS is down 10.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 8.3%.

Tarsus Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$15.86), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Tarsus Pharmaceuticals

Company profile

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Bobak R. Azamian M.D.
Headquarters
Irvine, CA
Employees
370
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Tarsus Pharmaceuticals generated $451.4 million in revenue, up 146.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Tarsus Pharmaceuticals reported a net loss of $66.4 million, compared with a loss of $115.6 million a year earlier. Operating margin was -15.7%.

Tarsus Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$451.36M$182.95M$17.45M$25.82M$57.03M
Growth+146.71%+948.62%-32.42%-54.73%—
Net income$-66.42M$-115.55M$-135.89M$-62.09M$-13.83M
EPS (diluted)$-1.59$-3.07$-4.62$-2.52$-0.67

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$103.44+41.68%

  • Strong buy 1
  • Buy 9
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $88.00High $116.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-14.40 vs $-1.43
Surprise
-906.99%

TARS news

All TARS news

Tarsus Pharmaceuticals peers

Health Care sector
TARS peer companies
CompanyPrice% ChgMarket capCompare
RLAYRelay Therapeutics Inc.16.12+1.32%$3.56Bvs TARS
CRSPCRISPR Therapeutics AG39.10+0.44%$3.79Bvs TARS
IOVAIovance Biotherapeutics Inc.6.90-5.61%$3.19Bvs TARS
DNLIDenali Therapeutics Inc.18.45+1.37%$2.96Bvs TARS
VCELVericel Corporation57.52-1.27%$2.94Bvs TARS
ADMAADMA Biologics Inc13.17-1.27%$2.92Bvs TARS
ADPTAdaptive Biotechnologies Corporation27.93-0.43%$4.52Bvs TARS
BEAMBeam Therapeutics Inc.20.90-0.19%$2.16Bvs TARS

Indexes, lists and sector

Tarsus Pharmaceuticals stock FAQ

What is Tarsus Pharmaceuticals's stock price today?

TARS last traded at $73.01 as of Nov 20, 4:00 PM EST, down 6.00% on the day. Prices are delayed at least 15 minutes.

Who is Tarsus Pharmaceuticals's CEO?

Dr. Bobak R. Azamian M.D. is the chief executive officer of Tarsus Pharmaceuticals Inc., which has about 370 employees.

What is the TARS 52-week high?

The 52-week high for TARS is $91.53 and the 52-week low is $53.89. The stock is currently 20.2% below its high.

Compare TARS